

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

PENNSYLVANIA EMPLOYEE BENEFIT TRUST FUND, on behalf of itself and all others similarly situated, JOSEPH MACKEN, and COMMISSIONER LINDA A. WATTERS

Plaintiffs,

V.

ZENECA, INC. and ASTRAZENECA
PHARMACEUTICALS, LP,

Defendants.

Civ. No. 05-075-SLR
(Lead Case)

DEFENDANTS' APPENDIX IN SUPPORT OF THEIR MOTION TO DISMISS

OF COUNSEL:

Peter I. Ostroff
Mark E. Haddad
Alycia A. Degen
Joshua E. Anderson
SIDLEY AUSTIN BROWN & WOOD LLP
555 West Fifth Street, Suite 4000
Los Angeles, CA 90013
(213) 896-6000

John W. Treece
Maja C. Eaton
Richard D. Raskin
SIDLEY AUSTIN BROWN & WOOD LLP
Bank One Plaza
10 South Dearborn Street
Chicago, IL 60603
(312) 853-7000
Attorneys for Defendants

MORRIS, NICHOLS, ARSHT & TUNNELL
Jack B. Blumenfeld (#1014)
R. Judson Scaggs, Jr. (#2676)
Natalie J. Haskins (#4472)
1201 North Market Street
P. O. Box 1347
Wilmington, DE 19899-1347
(302) 658-9200
Attorneys for Defendants

July 1, 2005

Defendants AstraZeneca Pharmaceuticals, L.P. and Zeneca Inc. respectfully submit this Appendix in Support of their Motion to Dismiss.

TAB

STATUTES

21 U.S.C. § 321	1
21 U.S.C. § 331	2
21 U.S.C. § 352	3
21 U.S.C. § 353	4
21 U.S.C. § 355	5

FEDERAL REGULATIONS

21 C.F.R. § 10.25	6
21 C.F.R. § 201.56	7
21 C.F.R. § 201.57	8
21 C.F.R. § 201.100	9
21 C.F.R. § 202.1	10
21 C.F.R. § 310.3	11
21 C.F.R. § 312.21	12
21 C.F.R. § 314.50	13
21 C.F.R. § 314.81	14
21 C.F.R. § 314.105	15
21 C.F.R. § 314.125	16
21 C.F.R. § 314.126	17

FEDERAL REGISTER

60 Fed. Reg. 42,581-82 (Aug. 16, 1995)	18
----------------------------------------	----

OTHER AUTHORITIES

3 Trade Reg. Rep. (CCH) ¶ 7765	19
--------------------------------	----

TAB

<i>Working Agreement Between FTC and Food and Drug Administration</i> , 4 Trade Reg. Rep (CCH) ¶ 9851 (1971)	20
FDA Division of Drug Marketing, Advertising, and Communications Frequently Asked Questions (http://www.fda.gov/cder/ddmac/FAQS.HTM)	21
Letter from Thomas W. Abrams, Director, Division of Drug Marketing, Advertising and Communications, to Fred Hassan, President and CEO, Pharmacia Corp. (Feb. 1, 2001) (http://www.fda.gov/cder/warn/2001/DD8432.pdf)	22
FDA, <i>Guidance for Industry: Clinical Studies Section of Labeling for Prescription Drugs and Biologics – Content and Format</i> (July 2001) (DRAFT) (http://www.fda.gov/guidance/1890dft.htm)	23
Statement of Janet Woodcock, M.D. before the Sen. Special Comm. on Aging, July 22, 2003 (www.hhs.gov/asl/testify/t030722b.html)	24
Letter from Lisa L. Stockbridge, Regulatory Review Officer, Division of Drug Marketing, Advertising, and Communications, to Vincent DeStefano, Associate Director of Regulatory Affairs, Novartis (Dec. 3, 2002) (http://www.fda.gov/cder/warn/2002/10972.pdf)	25

#472554